Performance of Cementless Hip Arthroplasty Stem Types Based on Consolidated Large Registry Data by Logan E. Finger, MD, Matthew F. Gong, MD, Asher Mirvish, BS, Alexandra S. Gabrielli, MD, Ahmad P. Tafti, PhD, Michael J. O’Malley, MD, Brian A. Klatt, MD, Johannes F. Plate, MD, PhD

“…Methods: Joint registry data on the reported overall cases and revisions for each cementless stem brand were collected from the annual reports of the American Joint Replacement Registry (2021), United Kingdom National Joint Registry (2021), New Zealand Joint Registry (2020), and Australian Orthopaedic Association National Joint Replacement Registry (2021). …”
Get full text

Budget Impact of Rivaroxaban for the Prevention of Thromboembolic Events after Hip or Knee Replacement in Spain by Xavier Granero Xiberta, Antonio Murcia, José Ricardo Troncoso Durán, Claudio Gómez Zubeldia, Aleix Llorac Moix, Ruth Graefenhain De Codes, Maria Giovana Ferrario, Luis Lizán

“…**Results:** The difference in cost per patient undergoing THR or TKR with rivaroxaban versus enoxaparin was -€140.69 including event rates and resource use from the Spanish XAMOS population, and -€110.54 when considering event rates and resource use from the multinational XAMOS population (including but not limited to European [Spain, France, Italy, United Kingdom, Portugal, etc.], American [Canada, Mexico, Colombia, Venezuela, etc.], Asian [China, etc.] and Australian countries). …”
Get full text